A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19

de Jesús Ascencio-Montiel et al., Archives of Medical Research, doi:10.1016/j.arcmed.2022.01.002

Jan 2022

Source PDF All Studies Meta AnalysisMeta

Retrospective 28,048 COVID+ patients in Mexico, 7,898 receiving a treatment kit including low dose ivermectin, AZ, aspirin, and acetaminophen, shower lower mortality/hospitalization for those receiving the kit. Delivery of the treatment kit was based on availability in the medical units. Adherence is unknown and may be low. Adjusted results are only provided for combined mortality/hospitalization.

This is the 77th of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion). 46 studies are RCTs, which show efficacy with p=0.00000014.

Important missing comments or errors? Let us know.

This study includes aspirin and ivermectin.

risk of death/hospitalization, 59.0% lower, RR 0.41, p < 0.001, treatment 7,898, control 20,150, adjusted per study, multivariable, primary outcome.

risk of death/hospitalization, 71.0% lower, RR 0.29, p < 0.001, treatment 5,557, control 12,526, adjusted per study, with phone call followup, multivariable.

risk of death, 15.0% lower, RR 0.85, p = 0.16, treatment 101 of 7,898 (1.3%), control 303 of 20,150 (1.5%), NNT 445, unadjusted, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.

risk of mechanical ventilation, 9.1% lower, RR 0.91, p = 0.51, treatment 77 of 7,898 (1.0%), control 216 of 20,150 (1.1%), NNT 1031, unadjusted, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.

risk of hospitalization, 47.6% lower, RR 0.52, p < 0.001, treatment 485 of 7,898 (6.1%), control 2,360 of 20,150 (11.7%), NNT 18, unadjusted, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.

risk of progression, 41.8% lower, RR 0.58, p < 0.001, treatment 435 of 7,898 (5.5%), control 1,906 of 20,150 (9.5%), NNT 25, unadjusted, ER, excluded in exclusion analyses: unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

de Jesús Ascencio-Montiel et al., 24 Jan 2022, retrospective, Mexico, peer-reviewed, 10 authors, dosage 6mg days 1-2, this trial uses multiple treatments in the treatment arm (combined with AZ, acetaminophen, aspirin) - results of individual treatments may vary.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19

Iván De Jesús Ascencio-Montiel, Juan Carlos Tomás-López, Verónica Álvarez-Medina, Luisa Estela Gil-Velázquez, Hortensia Vega-Vega, Héctor Raúl Vargas-Sánchez, Manuel Cervantes-Ocampo, Miguel Ángel Villasís-Keever, Cesar Raúl González-Bonilla, Célida Duque-Molina

Archives of Medical Research, doi:10.1016/j.arcmed.2022.01.002

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

Abaleke, Abbas, Abbasi, Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, Arch Med Res

Bell, Norris-Grey, Luintel, Implementation and evaluation of a COVID-19 rapid follow-up service for patients discharged from the emergency department, Clin Med (Lond)

Bermúdez, Manso, Sánchez, Usefulness and acceptance of telephone monitoring by a virtual assistant for patients with COVID-19 following discharge, Rev Clin Esp (Barc)

Fagherazzi, Goetzinger, Rashid, Digital Health Strategies to Fight COVID-19 Worldwide: Challenges, Recommendations, and a Call for Papers, J Med Internet Res

Gootenberg, Kurtzman, Mara, Developing a pulse oximetry home monitoring protocol for patients suspected with COVID-19 after emergency department discharge, BMJ Health Care Inform

Hill, Garratt, Levi, Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection, Open Forum Infect Dis

Jaffery, Slakey, Zodda, Case Report: Disposition of Symptomatic Probable COVID-19, Clin Pract Cases Emerg Med

Lam, Sehgal, Andany, A virtual care program for outpatients diagnosed with COVID-19: A feasibility study, CMAJ Open

López, Lozano, Ruiz, Seguimiento telemático de COVID-19: Experiencia de un hospital terciario, An Pediatr (Barc)

Motta, Silva, Da, Borguezan, An emergency system for monitoring pulse oximetry, peak expiratory flow, and body temperature of patients with COVID-19 at home: Development and preliminary application, Arch Med Res

Vallejos, Zoni, Bangher, Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial, BMC Infect Dis

Vindrola-Padros, Singh, Sidhu, Remote home monitoring (virtual wards) for confirmed or suspected COVID-19 patients: a rapid systematic review, E Clinical Medicine

Working, Epidemic Response, Cc, Dc, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China, Zhonghua Liu Xing Bing Xue Za Zhi

Wurzer, Spielhagen, Siegmann, Remote monitoring of COVID-19 positive high-risk patients in domestic isolation: A feasibility study, PLoS One

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0